6Muller FM , Weig M , Peter J, et al. Azole crossresistance to ketoconazole, fluconazole, itraconazole and voriconazole inclinical Candida albicans isolates from HIV-infected children with oropharyageal candidosis[JJ .J Antimierob Chemother, 2000, 46(2) :338-341. 被引量：1
7Magill SS, Shields C, Sears CL, et al. Triazole rroes-resistance among Candida spp: case report, Occurrence among bloods tream isolates, and implications for antifungaltherapy[J]. J Clin Microbiol, 2006, 44 (2): 529-535. 被引量：1
8Loeffler J, Stevens DA. Antifungal drug resistance [J]. ClinInfect Dis, 2003, 36(Suppl 1) :3-41. 被引量：1
9Falagas M E, Vardakas KZ, Michalopoulos A. In metanalysis itraconazole is superior to fluconazole for prophylaxisof systemic fungal infection in the treatment of rice et al[J]. British Journal of Haematology, 2006,132(5) : 658-659 被引量：1
10Groll A H, Piscitelli S C, Waslsh T J. Clinical pharmacology of systemic antifungal agents:A comprehensive review of agent in clinical agent investigational compounds and putative targets for antifungal drug development [JJ. Adv pharmacol, 1998, 44 : 343. 被引量：1
8[3]White MH,Anaissie EJ,Kusne S,et al. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis, 1997,24:635 ～ 642 被引量：1
9[4]Johnson HB, Kaeffmen CA. Voriconazole: An ewtriazole antifungalagent. Clin Infect Dis,2003,36:610 ～617 被引量：1
10[5]Uchida K, Yokota N, Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int J AntimicrobAgents ,2001,18:167 ～ 172 被引量：1
